Literature DB >> 21208919

The necessity and quandaries of dengue vaccine development.

Stephen J Thomas.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21208919      PMCID： PMC3071120          DOI： 10.1093/infdis/jiq060

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  89 in total

1.  Technology evaluation: ChimeriVax-DEN, Acambis/Aventis.

Authors:  Taff Jones
Journal:  Curr Opin Mol Ther       Date:  2004-08

2.  Locally acquired Dengue--Key West, Florida, 2009-2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-21       Impact factor: 17.586

3.  Antibody-dependent enhancement in dengue virus infections.

Authors:  Donald S Burke; Srisakul Kliks
Journal:  J Infect Dis       Date:  2006-02-15       Impact factor: 5.226

Review 4.  Immunopathological mechanisms in dengue and dengue hemorrhagic fever.

Authors:  Sharone Green; Alan Rothman
Journal:  Curr Opin Infect Dis       Date:  2006-10       Impact factor: 4.915

5.  The health and economic impact of dengue in Latin America.

Authors:  Jaime R Torres; Julio Castro
Journal:  Cad Saude Publica       Date:  2007       Impact factor: 1.632

6.  Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.

Authors:  Wellington Sun; Dennis Cunningham; Steven S Wasserman; Judith Perry; J Robert Putnak; Kenneth H Eckels; David W Vaughn; Stephen J Thomas; Niranjan Kanesa-Thasan; Bruce L Innis; Robert Edelman
Journal:  Hum Vaccin       Date:  2009-01-27

7.  Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance.

Authors:  Stephen J Thomas; Ananda Nisalak; Kathryn B Anderson; Daniel H Libraty; Siripen Kalayanarooj; David W Vaughn; Robert Putnak; Robert V Gibbons; Richard Jarman; Timothy P Endy
Journal:  Am J Trop Med Hyg       Date:  2009-11       Impact factor: 2.345

8.  Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum.

Authors:  J D Chulay; I Schneider; T M Cosgriff; S L Hoffman; W R Ballou; I A Quakyi; R Carter; J H Trosper; W T Hockmeyer
Journal:  Am J Trop Med Hyg       Date:  1986-01       Impact factor: 2.345

9.  Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.

Authors:  Sriluck Simasathien; Stephen J Thomas; Veerachai Watanaveeradej; Ananda Nisalak; Célia Barberousse; Bruce L Innis; Wellington Sun; J Robert Putnak; Kenneth H Eckels; Yanee Hutagalung; Robert V Gibbons; Chunlin Zhang; Rafael De La Barrera; Richard G Jarman; Wipa Chawachalasai; Mammen P Mammen
Journal:  Am J Trop Med Hyg       Date:  2008-03       Impact factor: 2.345

10.  Cost of dengue and other febrile illnesses to households in rural Cambodia: a prospective community-based case-control study.

Authors:  Rekol Huy; Ole Wichmann; Mark Beatty; Chantha Ngan; Socheat Duong; Harold S Margolis; Sirenda Vong
Journal:  BMC Public Health       Date:  2009-05-27       Impact factor: 3.295
View more
  20 in total

1.  Dengue vaccine: a valuable asset for the future.

Authors:  Harashish Jindal; Bhumika Bhatt; Jagbir Singh Malik; Shashikantha S K
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 2.  Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment.

Authors:  Tim K Mackey; Bryan A Liang; Raphael Cuomo; Ryan Hafen; Kimberly C Brouwer; Daniel E Lee
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

3.  Dengue human infection model: introduction.

Authors:  M Cristina Cassetti; Stephen J Thomas
Journal:  J Infect Dis       Date:  2014-06-15       Impact factor: 5.226

4.  Improving dengue virus capture rates in humans and vectors in Kamphaeng Phet Province, Thailand, using an enhanced spatiotemporal surveillance strategy.

Authors:  Stephen J Thomas; Jared Aldstadt; Richard G Jarman; Darunee Buddhari; In-Kyu Yoon; Jason H Richardson; Alongkot Ponlawat; Sopon Iamsirithaworn; Thomas W Scott; Alan L Rothman; Robert V Gibbons; Louis Lambrechts; Timothy P Endy
Journal:  Am J Trop Med Hyg       Date:  2015-05-18       Impact factor: 2.345

Review 5.  Recent progress in dengue vaccine development.

Authors:  Jianchun Wei; Hui Chen; Jing An
Journal:  Virol Sin       Date:  2014-12-24       Impact factor: 4.327

6.  Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies.

Authors:  Niyati Khetarpal; Rahul Shukla; Ravi Kant Rajpoot; Ankur Poddar; Meena Pal; Sathyamangalam Swaminathan; Upasana Arora; Navin Khanna
Journal:  Am J Trop Med Hyg       Date:  2016-11-07       Impact factor: 2.345

7.  Treatment of dengue fever.

Authors:  Senaka Rajapakse; Chaturaka Rodrigo; Anoja Rajapakse
Journal:  Infect Drug Resist       Date:  2012-07-23       Impact factor: 4.003

8.  Sculpting humoral immunity through dengue vaccination to enhance protective immunity.

Authors:  Wayne D Crill; Holly R Hughes; Nicole B Trainor; Brent S Davis; Matt T Whitney; Gwong-Jen J Chang
Journal:  Front Immunol       Date:  2012-11-08       Impact factor: 7.561

9.  A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults.

Authors:  Stephen J Thomas; Kenneth H Eckels; Isabelle Carletti; Rafael De La Barrera; Francis Dessy; Stefan Fernandez; Robert Putnak; Jean-Francois Toussaint; Wellington Sun; Kristen Bauer; Robert V Gibbons; Bruce L Innis
Journal:  Am J Trop Med Hyg       Date:  2012-12-03       Impact factor: 2.345

10.  Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies.

Authors:  Shailendra Mani; Lav Tripathi; Rajendra Raut; Poornima Tyagi; Upasana Arora; Tarani Barman; Ruchi Sood; Alka Galav; Wahala Wahala; Aravinda de Silva; Sathyamangalam Swaminathan; Navin Khanna
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.